BrainsWay (BWAY) said Monday it has launched a multicenter clinical trial to assess its Deep TMS 360 system in people with alcohol use disorder.

The randomized, double-blind trial will enroll over 200 adults with moderate to severe AUD for about six months of active or sham treatment, with the proportion of patients reporting no heavy drinking days during the first four months of treatment as primary endpoint, the company said.

Participants will also receive behavioral and educational support during the study, BrainsWay said.

The trial will take place at multiple sites in the US, Israel, and Sweden, it added.

Shares of BrainsWay were down about 3% in recent trading Monday.

Price: 15.29, Change: -0.47, Percent Change: -2.98